1-[4-(4-bromophenyl)-3-hydroxypyrazol-1-yl]ethanone | 852470-92-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-[4-(4-bromophenyl)-3-hydroxypyrazol-1-yl]ethanone
• 英文别名: 2-acetyl-4-(4-bromophenyl)-1H-pyrazol-5-one
• CAS: 852470-92-9
• 化学式: C₁₁H₉BrN₂O₂
• 分子量: 281.109
• InChiKey: NKIBKYONNFUXQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  4-(4-bromophenyl)-1H-pyrazol-3-ol 、 乙酸酐 在 吡啶 作用下， 反应 1.0h， 生成 1-[4-(4-bromophenyl)-3-hydroxypyrazol-1-yl]ethanone
  参考文献：
  名称：

  Pyrazolyl derivatives, preparation process and intermediates of this process as medicinal products and pharmaceutical compositions containing them

  摘要：

  本发明涉及公式(I)的新颖衍生物，其中A是，如果存在的话，(C1-C6)烷基，(C3-C6)烯基，(C3-C6)炔基，(C3-C7)环烷基或(C5-C7)环烯基，R1是NR6R7，(C4-C7)氮杂环烷基，(C5-C7)氮杂环烯基，(C5-C9)氮杂双环烷基或(C5-C9)氮杂双环烯基；A-R1是这样的，即R1的氮原子和吡唑的1位的氮原子之间至少被两个碳原子分隔，R3是H，卤素，OH，SH，NH2，ORc，SRc，SORa，SO2Ra，NHCHO，NRaRb，NHC(O)Ra，NHC(S)Ra或NHSO2Ra，R4是芳基或杂芳基；R5是H，卤素，CF3，CHF2，CH2F，直链或支链(C1-C6)烷基或(C3-C7)环烷基，它们的外消旋体、对映体和非对映异构体，以及它们的混合物，它们的互变异构体和它们的药学上可接受的盐。

  公开号：

  US20050165005A1

文献信息

• Complex catalyst, process for producing the complex catalyst, and process for producing alchohol derivative with the complex catalyst
  申请人：——

  公开号：US20040077487A1

  公开（公告）日：2004-04-22

  There are provided (asymmetric) complex catalysts comprising metal complexes and Lewis acids as components, the metal complex being of formula (1): 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same or different and are independently hydrogen, halogen, alkyl or the like; one of R 9 and R 10 is hydrogen and the other is alkyl of 1 to 4 carbon atoms or the like; Q is a single bond or alkylene of 1 to 4 carbon atoms; M is a metal ion; and A is a balancing counter ion or ligand; processes for the production of these complex catalysts; processes for the production of (optically active) alcohol derivatives, characterized in that cyclic ether compounds are reacted with phenol derivatives in the presence of these complex catalysts; and further processes for producing (optically active) nitrogen-containing heterocyclic compounds by reacting these alcohol derivatives with halogenated nitrogen-containing heterocyclic compounds in the presence of a base.

  提供了由金属配合物和路易斯酸组成的（不对称的）复杂催化剂，其中金属配合物的化学式为（1）：1其中R1、R2、R3、R4、R5、R6、R7和R8相同或不同，独立地是氢、卤素、烷基或类似物；R9和R10中的一个是氢，另一个是1至4个碳原子的烷基或类似物；Q是单键或1至4个碳原子的烷基；M是金属离子；A是平衡的反离子或配体；制备这些复杂催化剂的方法；制备（光学活性的）醇衍生物的方法，其特征在于在这些复杂催化剂的存在下，环氧化合物与酚衍生物反应；以及在碱的存在下，通过将这些醇衍生物与卤素化的含氮杂环化合物反应，制备（光学活性的）含氮杂环化合物的进一步方法。
• COMPLEX CATALYST, PROCESS FOR PRODUCING THE COMPLEX CATALYST, AND PROCESS FOR PRODUCING ALCOHOL DERIVATIVE WITH THE COMPLEX CATALYST
  申请人：Sumitomo Chemical Company, Limited

  公开号：EP1380342B1

  公开（公告）日：2009-07-01
• DERIVES DE PYRAZOLE A TITRE DE MEDICAMENTS POUR LE TRAITEMENT DES DEGENERESCENCES NEURONALES AIGUES OU CHRONIQUES
  申请人：Aventis Pharma S.A.

  公开号：EP1689720A1

  公开（公告）日：2006-08-16
• 急性または慢性神経退行を治療する薬剤の形態のピラゾリル誘導体
  申请人：アバンテイス・フアルマ・エス・アー

  公开号：JP4833078B2

  公开（公告）日：2007-12-13
• PYRAZOLYL DERIVATIVES, PREPARATION PROCESS AND INTERMEDIATES OF THIS PROCESS AS MEDICINAL PRODUCTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：GENEVOIS-BORELLA Arielle

  公开号：US20090170833A1

  公开（公告）日：2009-07-02

  The present invention relates to the novel derivatives of formula (I) in which A is, if it is present, a (C1-C6) alkyl, a (C3-C6) alkenyl, a (C3-C6) alkynyl, a (C3-C7) cycloalkyl or a (C5-C7) cycloalkenyl, R1 is an NR6R7, (C4-C7) azacycloalkyl, (C5-C7) azacycloalkenyl, (C5-C9) azabicycloalkyl or (C5-C9) azabicycloalkenyl group; A-R1 is such that the nitrogen of R1 and the nitrogen in the 1-position of the pyrazole are necessarily separated by at least two carbon atoms, R3 is an H, halogen, OH, SH, NH 2 , ORc, SRc, SORa, SO 2 Ra, NHCHO, NRaRb, NHC(O)Ra, NHC(S)Ra or NHSO 2 Ra, R4 is an aryl or heteroaryl; and R5 is an H, halogen, CF 3 , CHF 2 , CH 2 F, linear or branched (C1-C6) alkyl or (C3-C7) cycloalkyl, to their racemates, enantiomers and diastereoisomers and to their mixtures, their tautomers and to their pharmaceutically acceptable salts.